Stock Report: Geron Corp. (GERN) Report Updated: Jun 17, 2013 | Print This Page
Report Features:
Stock Analysis
Rating: Monthly View
| A |  |
 |
 |
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Rating: Weekly View
| This Week: | C  no change |
|---|---|
| Last Week: | C no change |
| Two Weeks Ago: | C no change |
Company Profile
Geron Corporation, a biopharmaceutical company, develops therapies for cancer. The company’s clinical development product candidates include Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of metastatic breast cancer, advanced non-small cell lung cancer, thrombocythemia, and myeloma; and GRN1005, a lipoprotein receptor-related protein-1 directed peptide-drug conjugate that is used to transport paclitaxel, an anti-cancer drug in the blood brain barrier. Its GRN1005 clinical development product candidate is in Phase II clinical trials for the treatment of brain metastases arising from breast cancer; and brain metastases arising from non-small cell lung cancer. Geron Corporation was founded in 1990 and is based in Menlo Park, California.
Recent News: Geron Corp.
| 2012-10-18 00:00:00 | Filing of certain prospectuses and communications in connection with business combination transactions - Form 425 |
| 2012-10-11 00:00:00 | Prospectus filed under Rule 424(b)(5) - Form 424B5 |
| 2012-10-11 00:00:00 | Prospectus filed under Rule 424(b)(5) - Form 424B5 |
| 2012-10-09 00:00:00 | Report of unscheduled material events or corporate changes - Form 8-K |
| 2012-10-09 00:00:00 | Pre-effective amendment to an S-3 filing - Form S-3/A |
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier's Portfolios
- Blue Chip GrowthTop blue chips
- Emerging GrowthTop small-caps
- Ultimate GrowthFastest-moving
- Platinum GrowthElite Model Portfolio